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The basis of maintenance of immune homeostasis is the close collaboration between the 
elements of innate and adaptive immunity. The humoral (complement system, antimicrobial 
peptides, cytokines) and cellular (phagocytes, natural killer (NK) cells and dendritic cells) 
components of innate immunity constitute the first line of immunological defense against 
intruder pathogens and they play a key role in triggering adaptive immune response. The 
humoral (cytokines, antibodies) and cellular elements (T and B lymphocytes) of adaptive 
immune response are activated following a certain latency period. However, the two defense 
systems do not function independently of each other, but they provide protection of the host 
organism in an intertwined way. The increased reactivity or reduced functioning of the immune 
system plays a key role in the pathogenesis of several gastroenterological diseases. In the 
course of our clinical research, we selected two gastroenterological patient groups (coeliac 
patients and cirrhosis patients) in which the dysfunction of the innate immune system plays a 
significant role in the pathogenesis of the disease and the developed complications. It is the 
common characteristic of the two diseases that the inflammation and structural and functional 
impairment of the small intestine walls lead to increased permeability, which, coupled with the 
altered bowel flora, results in chronic bacterial translocation. The presence of various bacteria 




Coeliac disease (CD, gluten-sensitive enteropathy, sprue) is an autoimmune enteropathy 
triggered by the gliadin component of gluten and mediated by the T cell, developed in 
genetically susceptible patients which also shows extraintestinal manifestation.  
The development of the disease is very diverse, there is little to be known about which factors 
affect symptom types. The clinical manifestation of the disease is either classic, when the signs 
and symptoms of malabsorption (diarrhoea, weight loss, steatorrhoea and growth failure) can 
be easily detected, or non-classic (gastrointestinal symptoms and/or extraintestinal 
manifestations) and asymptomatic. During the recent years, increasing number of non-classic 
and asymptomatic patients were diagnosed worldwide. 
The disease is characterised by the formation of several antibodies (e.g. anti-transglutaminase 
antibodies: TGA; anti-endomysium antibodies: EMA, anti-gliadin antibodies, anti-
deamidated gliadin peptide antibodies), even though the mechanisms in the background of 
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their generation and their specific role in the pathogenesis of the disease is not entirely known. 
The firstly detected anti-gliadin antibodies and the subsequently detected anti-reticulin 
antibodies are not used in CD diagnostics anymore due to their low sensitivity and specificity. 
Most recommendations refer to anti-TG2 and EMA. Currently, anti-synthetic deamidated 
gliadin peptide antibodies seem to be a viable option in CD diagnostics in certain cases. 
The antibodies generated against the carbohydrate epitopes of the cell walls of various 
bacteria are markers of complicated Crohn’s disease. The more frequent appearance of the 
anti-Saccharomyces cerevisiae antibody (ASCA) was described also in coeliac disease. At 
the same time, the frequency of the appearance and clinical CD-related significance of other 




Glycans are oligosaccharides consisting of identical monosaccharide units linked together with 
glycosidic bond. Glycans are present in the cell surfaces of red blood cells, immune cells and 
various microorganisms. Furthermore, these oligosaccharides are important molecules of the 
humoral and cellular immune system, as they play a key role in developing links between cells, 
as well as in the innate immune response and the antibodies generated against them detect the 
antigens consisting of the carbohydrate components on the surface of pathogens. This 
phenomenon explains why anti-glycan antibodies are considered to be a possible biomarker for 
inflammatory and autoimmune diseases. The anti-mannobioside Man(1.3) Man() 
carbohydrate epitope IgG antibody or AMCA IgG belongs to the group of anti-mannan 
antibodies. Anti-laminaribioside Glc(1.3)Glc(), and anti-chitobioside 
GlcNAc(1.4)GlcNAc() antibodies (ALCA IgG and ACCA IgA) are also anti-glycan 
antibodies. The anti-OmpC/anti-OMP IgA antibody is generated against the transport protein 
porin C in the outer membrane of Escherichia coli.  
The most frequently examined anti-mannan antibody is the anti-Saccharomyces cerevisiae 
antibody (ASCA IgG and IgA or gASCA), which is generated against the oligomannose 
structure in the cell wall of Saccharomyces cerevisiae that is found in bakers’ yeast and brewers’ 
yeast. As regards ASCA and other antibodies generated against microbial antigens, it can be 
stated that the exact mechanism and the significance of their development is not yet clarified. It 
is not known whether these antibodies have any role in the immune pathogenesis of 
inflammatory gastroenterological diseases [e.g. inflammatory bowel disease (IBD) or coeliac 
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disease] or their appearance is only the consequence of inflamed, permeable intestinal mucosa. 
Furthermore, the anti-microbial antibodies might represent genetic susceptibility because 
patients who have positive antibodies often carry mutations in the NOD2/CARD15 gene. 
Anti-microbial antibody formation has also been reported in CD. ASCAs remain the most 
widely investigated antibodies in this patient group but increasing experimental data are 
available on newly discovered antibodies such as anti-I2 or anti-OmpW (Bacteroides caccae 
TonB- linked outer membrane protein). 
 
Cirrhosis 
The various factors impairing liver cells (most often alcohol consumption, viral infection, non-
alcoholic steatohepatitis or autoimmune processes) result in typical histological lesions 
(necroinflammation, fibrogenesis) in the liver. As a result of the progression of these processes, 
it usually takes years or decades to develop definitive cirrhosis. In cirrhosis patients, the 
frequent reasons of the deterioration of clinical conditions are infections which have a 
fundamental role in the development of several complications, including variceal bleeding, 
hepatic encephalopathy, kidney failure and coagulation disorders. The development of 
bacterial infection quadruples the risk of mortality. 30% of patients die within a month 
following infection and another 30% die within one year. The prevention of bacterial infections 
is especially significant; therefore, it is necessary to early detect patients who run a great risk 
of such episodes. For a long time, only a few clinical forecast factors are known such as the 
Child-Pugh score (advanced stage and gastrointestinal bleeding). Cirrhosis patients are 
especially susceptible to bacterial infections and cirrhosis is one of the most frequent adaptive 
immune deficiency. The background of this phenomenon is the mechanisms affecting innate 
and adaptive immunity which are jointly referred to as cirrhosis-associated immune 
dysfunction (CAID). 
The intestinal mucosal barrier in cirrhosis patients is impaired for various reasons, resulting in 
pathologic bacterial translocation and the amount of immunogenic bacterial products increases 
in the circulation. These products increase the pro-inflammatory processes which lead to the 
impairment of the liver tissue and the insufficient functioning of the soluble and cellular 




Complement system – lectin pathway 
The complement system is an important element of innate immunity. The complement system 
can be activated in three ways: the classic, alternative and lectin pathway. The lectin pathway 
is activated by the binding of carbohydrates on the surface of MBL or ficolins and pathogens. 
Most molecules of the lectin pathway are generated in the liver and they have a key role in the 
natural defense of the host organism against pathogens. Mannose-binding lectin, ficolins (FCN) 
and collectins act as soluble pattern recognition molecules (sPRM), while mannose-binding 
lectin associated serine proteases (MASP) are the effector molecules of pathogen elimination. 
So far, human analyses led to the identification of three ficolins: L-ficolin (FCN-2), H-ficolin 
(FCN-3) and M-ficolin (FCN-1). The main activator of the system is MASP-2 which creates a 
complex with MBL, H-ficolin and L-ficolin and circulates in the plasm. MASP-2 is activated 
if MBL or ficolins are bound to the pathogen-associated molecular pattern. As a next step, 
MASP-2 is able to split C2 and C4, resulting in the C3 convertase C4bC2b.  
The low level of functional proteins increases the risk of various infections, mainly in the case 
of diseases associated with immunosuppression. However, the role of functional proteins in 
bacterial infection is less known.  
 
OBJECTIVES 
Coeliac patient group 
We hypothesized that newly discovered inflammatory bowel disease (IBD)-associated 
antibodies (including anti-glycan antibodies and anti-OMP) may also be of importance in CD 
and aimed to determine the prevalence of these antibodies in a Hungarian cohort of adult CD 
patients in relation to clinical presentation, GFD and NOD2/CARD15 mutations. 
Cirrhosis patient group 
In this study, we aimed to assess the serum levels of various lectin pathway molecules in a large 
cohort of stable outpatients with cirrhosis and also their association with the disease specific 
characteristics. In addition, in a 5-year follow-up  observational study, we aimed to evaluate 
whether serum levels of various lectin pathway molecules constitute a risk for the development 
of cirrhosis-associated bacterial infections.  
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PATIENTS AND METHODS 
Patient groups 
Coeliac patients 
One-hundred and ninety consecutive, unrelated Hungarian adult patients with biopsy-proven 
CD (male/female: 71/119, mean age: 39.9 years, SD: 14.1) and 66 of their first degree relatives 
(siblings, mean age: 37.7 years, SD: 13.9) were investigated. The diagnosis of CD was based 
on small bowel biopsy showing severe villous atrophy with crypt hyperplasia (Marsh type III 
lesions) and elevated serum levels of antibodies against transglutaminase (TGA) and 
endomysium (EMA).  
Of the 190 patients, 82 patients’ sera were obtained at the time of diagnosis (Group CD1) and 
in 30 of these 82 patients further serum samples were re-evaluated for the same antibodies after 
adherence to long-standing GFD. The median follow-up period between these blood samplings 
was 28.5 mo [interquartile range (IQR): 18-52]. In the 108 remaining cases the diagnosis of 
CD had been established prior to this study and they adopted a strict GFD. These 108 patients 
were divided into two separate groups according to their current TGA and EMA status and 
dietary compliance at the time of the sampling. Thirty-three patients still had positive EMA 
and TGA results (Group CD2) and the median duration was here 3.5 mo (IQR: 1-11). The 
adequate compliance was indicated by reduced antibody titers as compared to those at 
diagnosis. The remaining 75 patients had negative EMA and normal TGA titers (Group CD3), 
median follow up: 21 mo (IQR: 6-85). Detailed clinical data concerning the clinical 
presentation of CD at diagnosis were classified as follows: (1) severe generalized 
malabsorption; (2) non-specific gastrointestinal symptoms that did not compromise the general 
condition; (3) iron deficiency anemia without major gastrointestinal complaints; (4) dermatitis 
herpetiformis; (5) silent disease (population screening); (6) other (autoimmune diseases, 
reduced bone mineral density, liver disease, brain disease). Patients were assigned to one of 
these major presentation types in a prospective manner, based on clinical and routine laboratory 
results at diagnosis. 
The control group consisted of 100 healthy, ethnically similar, blood donor individuals 
(male/female: 47/53, mean age: 36.6 years, SD: 9.1) who had normal findings on a thorough 
medical examination, blood pressure measurements, and routine laboratory tests. A second 
non- celiac gastrointestinal disease control group consisted of 48 patients with irritable bowel 
syndrome/diverticulosis without inflammation (male/female: 21/26, mean age 40.4 years, SD: 
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16.1). Further comparisons were performed with the previously published Crohn’s disease 
patient group in which the same antibodies were analysed. 
Cirrhosis patients 
The patients involved in this study constitute a part of the subgroup of 404 patients who were 
examined during regular or special follow-up visits in outpatient practice or due to acute 
decompensation (AD) episodes in hospital treatment between 1st May 2006 and 31st December 
2010. Serum samples of 378 patients (266 outpatients and 117 hospitalised patients due to AD 
episodes) were accessible for the analysis. In the course of a subsequent serological evaluation, 
we involved stable outpatients into the study, while AD patients were excluded. According to 
the usual criteria, one or more combinations of the following events were defined as acute 
decompensation: generation of a large quantity of ascites (stage II/III), acute hepatic 
encephalopathy, acute gastrointestinal bleeding and/or systemic bacterial infection. Refractory 
ascites patients were not involved either.  
Medical documentation containing clinical data was retrospectively analysed for the period 
prior to the observational follow-up study. At enrolment, disease severity assessed by liver-
oriented scores (Child-Pugh and MELD) and clinical stage of the diseases 
(compensated/decompensated) was determined. 
We involved patients in the follow-up study whose AD time and type which confirm their 
hospital admission were registered by the gastroenterologist. The follow-up period lasted for 5 
year or death/exclusion from follow-up. 85 patients (32%) died during follow-up, with the 
median period until death being 656 (IQR: 277-971) days. The median follow-up period of the 
181 surviving patients was 1107 (IQR: 411-1825) days. 
The definition of the appearance of clinically significant bacterial infections (spontaneous 
bacterial peritonitis, urinary tract infection, pneumonia and other infections of the skin and soft 
tissue, as well as biliary, mouth and digestive tract infection, osteomyelitis, endocarditis, 
bacterial infection of unknown origin without location-specific infection in the case of positive 
haemoculture) was based on carefully performed clinical, laboratory and imaging 
examinations.  
The healthy control group consisted of 160 age- and gender-matched   individuals (male/female:   
72/88,   age:  51.5±16.9 years) selected from consecutive blood donors in Debrecen. The control 





Identification of antimicrobial antibodies 
We used serum samples obtained from peripheral blood which were stored at -80ºC until use. 
The presence of antimicrobial antibodies was determined with the ELISA method, using 
commercially available kits in accordance with the instructions of the manufacturer: gASCA 
IgG, AMCA IgG, ALCA IgG, ACCA IgA (IBDX®, Glycominds Ltd., Lod, Israel), ASCA IgG, 
ASCA IgA and OMP IgA (QUANTA Lite™ OMP PLUS ELISA, INOVA Diagnostics, San 
Diego, CA). The results were presented as arbitrary units, which were calculated based on 
sample and calibrator optical density. Cut-off levels used for the determination of positivity 
were according to the manufacturers’ guidelines: 50, 100, 60 and 90 U/mL for gASCA IgG, 
AMCA IgG, ALCA IgG, ACCA IgA, respectively, and 25 U/mL for anti-OMP. 
Detection of NOD2/CARD15 mutations 
One-hundred and thirty-four CD patients and 100 healthy control subjects were eligible for 
NOD2/CARD15 mutation analysis. Major NOD2/CARD15 mutations (SNP 8, 12 and 13) were 
determined by denaturing high-performance liquid chromatography (dHPLC, Wave DNA 
Fragment Analysis System, Transgenomic Limited, UK). Sequence variation, observed in the 
dHPLC profile, was sequenced on both strands to confirm the alteration. Sequencing reactions 
were performed with the ABI BigDye Terminator Cycle Sequencing Kit v1.1 (Applied 
Biosystems, Foster City, CA) and samples were sequenced on an ABI Prism 310 Genetic 
Analyzer (Applied Biosystems, Foster City, CA) 
Examination of the lectin system 
Blood samples were obtained at enrolment from each patient and were frozen at -70°C until 
testing. Serum level of MASP-2 was determined using the ELISA method, according to the 
manufacturer’s instructions (Hycult Biotechnology, Uden, Netherlands). Samples were 
measured in duplicates on the same plate, and the mean values were used. Between runs, 
coefficients of variation (CV) were 8%. The limit of detection was 1.6 ng/mL. According to 
literature data, serum level of <100ng/ml was considered as MASP-2 deficiency. 
We set up a sandwich ELISA system to determine serum level of L-ficolin (FCN-2) and H-
ficolin (FCN-3). Briefly, microtiter plates (flat bottom, high binding capacity, Greiner Bio-One 
Hungary, Mosonmagyarovar, Hungary) were coated for 6 hours at 37°C with 0.75 μg/ml 
monoclonal mouse anti-human Ficolin-L (clone GN4) and Ficolin-H (clone 4H5) antibodies 
(HyCult Biotechnology) in carbonate/bicarbonate buffer (pH 9.6). Different dilutions of the 
sera (1/10 for Ficolin-L, 1/1000 for Ficolin-H) were then incubated in duplicates for overnight 
at +4°C in a wet chamber together with a serial dilution of Ficolin-L and Ficolin-H standards 
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(recombinant human Ficolin-L and Ficolin-H; R&D Systems Inc., Minneapolis, MN, USA). 
Serum standards concentrations ranged from 2.3 ng/ml to 150 ng/ml for Ficolin-L and from 
0.8 ng/ml to 50 ng/ml for Ficolin-H and were included in each run. After washing three times, 
biotinylated polyclonal goat anti-human Ficolin-L and Ficolin-H antibodies (R&D Systems 
Inc., Minneapolis, MN, USA) – 0.15 μg/ml concentration in phosphate-buffered saline (PBS) 
with 0.1% bovine serum albumin (BSA) at a pH 7.4 – were added for 2.5 hours at room 
temperature and followed by another washing step. Avidin–biotinylated-peroxidase-conjugate 
(Vectastain, Vector Laboratories Inc., Burlingame, CA) at 1:1000 dilution was added and 
incubated for 30 min at room temperature in a wet chamber. Color was developed with 
tetramethyl-benzidine dihydrochloride (TMB; Sigma–Aldrich, Schnelldorf, Germany), 
stopped with 2M H2SO4, and read immediately at 450 nm in a Labsystem Multiscan MS plate 
reader (Thermo Scientific, Budapest, Hungary). The calculation of results was performed using 
the Genesis software program with four parametric logistic curve fitting. 
In the case of duplicated samples, if the coefficients of variation (CV) were >20%, we repeated 
the measurement. The CV was 17% for FCN-2 and 14% for FCN-3 in between runs. Since no 
definition exists for FCN deficiencies in the present study, low level of FCN-2 (<427ng/ml) 
and FCN-3 (<4857ng/ml) were determined arbitrary corresponding to the 25th serum level 
percentiles of the patients.  
Statistical analysis 
The distribution of constant variables was analysed using the Shapiro-Wilk W test. The data 
was presented in accordance with the distribution in the form of median (percentile range: 25-
75), mean ± standard deviation and number of cases (%). 
t-test with separate variance estimates, χ2-test, χ2-test with Yates correction and likelihood ratio 
(LR) test were calculated to evaluate differences between various groups of CD patients and 
controls, as well as within subgroups of CD patients, as appropriate. Sensitivities, specificities, 
positive and negative likelihood ratios were calculated to determine the predictive power of 
gASCA, AMCA, ALCA, ACCA, OMP or the combination of these markers in distinguishing 
between CD and controls. Spearman’s rank order correlation was calculated to test the 
association between anti- glycan/OMP and TGA levels. Two-sided t-test for independent 
samples with separate variance estimates and ANOVA with post hoc Scheffe test were used to 
analyse the association between anti-glycan antibody titers and clinical symptoms at diagnosis. 
A P value of <0.05 was considered as significant.  
Categorical variables were compared using Fisher’s exact test or χ2test with Yates correction, 
as appropriate. Continuous variables were compared with Mann-Whitney U test or Kruskal-
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Wallis H test with Dunn’s multiple comparison post hoc analysis. Paired samples were analysed 
by Wilcoxon signed rank test. The Spearman’s nonparametric rank correlation test was used to 
determine correlations. 
The association between categorical clinical variables or serum levels of lectin pathway 
molecules and adverse disease outcomes during follow-up were assessed by Kaplan-Meier 
analysis and univariate Cox-regression analysis. The significance of subgroups was evaluated 
with log-rank test. Multivariate analyses were performed with backward elimination procedure 
and likelihood ratio test to identify independent risk factors.  Associations are given as hazard 
ratio [HR] with 95% confidence intervals [CI].For statistical analysis and graphical presentation 
the SPSS 22.0 [SPSS, Chicago, IL], and GraphPad Prism 6 [San Diego, CA] programs were 
used. A 2-sided probability value of <0.05 was considered to be statistically significant. 
  
RESULTS 
Analysis of antimicrobial antibodies in coeliac disease 
The frequency of gASCA IgG, AMCA IgG,  and ACCA IgA  was significantly higher at the 
time of diagnosis of CD than in healthy and non-celiac gastrointestinal control groups. 
However, the frequency of ALCA IgG and anti-OMP positivity in the patients was similar to 
those in control groups. No difference was found between healthy subjects and GI controls 
based on the presence of these antibodies. For that reason, we only used the healthy subjects as 
a control group in the subsequent comparisons. When calculating the sensitivity and specificity 
of the different markers based on the cut-off values suggested by the manufacturer, 65.9% of 
the CD patients were positive for at least one of the tested anti-microbial antibodies at the time 
of diagnosis. Except ALCA, all anti-glycan and anti-OMP antibodies were specific for 
untreated CD. However, the overall sensitivity was low (gASCA: 39.0%, AMCA: 35.4%, 
ACCA: 37.8%). Compared to healthy controls, gASCA, AMCA, and ACCA were associated 
with a moderate increase in the likelihood of CD, respectively. The positivity of any anti- glycan 
antibody significantly increased the likelihood for untreated CD. 
Detailed clinical data on the symptoms at the time of diagnosis in Group CD1 was available 
in 78 patients out of 82. Of the 78 patients, 32 (41%) presented with severe malabsorption, 
34 (43.6%) with non-specific or minor gastrointestinal symptoms, 9 (11.5%) with iron 
deficiency anemia, and 3 (3.9%) with other symptoms. The titers of the anti-glycan antibodies 
varied according to the presenting symptoms. Patients with severe malabsorption more 
frequently had multiple antibodies (P = 0.019) while in those with non- specific gastrointestinal 
symptoms or iron deficiency anaemia no seroreactivity or reactivity against only one glycan 
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components was more commonly seen (Table 4). Out of the CD patients with multiple 
antibodies positivity, 65.4% were diagnosed because of malabsorption, which was significantly 
higher than in CD patients with another serotype group (0 = 26.9%, or 1 = 34.8%, P = 0.019). 
Significant correlation was observed between the anti-glycan antibodies and the TGA level 
(pgASCA < 0.001, R = 0.39; pAMCA = 0.01, R = 0.28; pALCA = 0.006, R = 0.23; pACCA 
< 0.0001, R =0.53; p antiOMP = 0.001, R = 0.25, using Spearman’s correlation test). Similarly, 
positive correlation was found between EMA IgA and gASCA (p < 0.001), AMCA (p < 
0.001), ACCA (p< 0.0001), or any anti-glycan (p < 0.0001) antibody, while there was no 
correlation in the case of anti-OMP. 
In the group of 30 patients who were evaluated both at diagnosis and following a long term GFD 
(subgroup of Group CD1), initial positivity for anti-glycan antibodies (gASCA in 12, AMCA in 
9, and ACCA in 11 patients) observed at diagnosis was lost after GFD. The titer of each antibody 
decreased significantly after adherence to GFD (P < 0.001 for each). Anti-OMP antibody 
positivity behaved similarly, with all but one of 14 patients positive at diagnosis becoming 
negative after GFD, but the titer significantly decreased also in the case of this patient during 
the 135-day-long GFD. 
The prevalence of NOD2/CARD15 mutation in CD (19/134, 14.2%) did not differ from 
that in the control group (16/100, 16%). Additionally, we did not observe any association 
between symptoms at presentation or anti-glycan antibody positivity and the presence of 
NOD2/CARD15 variants. 
Analysis of lectin pathway molecules in cirrhosis patients 
FCN-2 and FCN-3 levels were significantly lower in cirrhosis patients than in the control 
subjects (FCN-2: 505[426–596] vs 769 [629–1145] p<0.001 and FCN-3: 7301[4857–10601] vs 
10797 [9017–13867] p<0.001). The MASP-2 level was also significantly lower (MASP-2: 
212[126–359] vs 412 [285–586]), while MASP-2 deficiency (<100 ng/ml) was also more 
frequently observed in cirrhosis patients (19.5% vs 2% p<0.001). 
In cirrhosis, levels of all three lectin pathway molecules decreased gradually according to 
disease severity, as rated by the Child-Pugh stage. Furthermore, both types of the FCNs but not 
the MASP-2 levels were significantly lower in patients with ascites as compared to those 
without. 
FCN levels were also associated with disease etiology to some degree. Both types of the FCNs 
levels were significantly lower in alcoholic as compared to non-alcoholic patients, but only in 
patients with Child A stage (FCN-2: 505 [440 – 562] vs. 548 [489 – 679] ng/ml, p=0.001 and 
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FCN-3: 7509 [5508 – 10897] vs. 10596 [7065 – 15379] ng/ml, p<0.001, respectively), or in 
those without ascites (data not shown). No similar association was found in the case of MASP-
2. 
Significant correlation was found between levels of lectin pathway molecules and laboratory 
markers of impaired renal and liver function and accordingly with liver-oriented scores (Child-
Pugh and MELD) or with the laboratory parameters of portal hypertension. 
The sequential changes of serum lectin levels were observed in the subgroup of stable 
outpatients (n=65). As a first step, the serum samples of 33 patients were analysed during 
subsequent outpatient follow-ups (655 [IQR: 246-1090] days passed between two samplings). 
No significant change was found in the serum level of either examined molecule (FCN-2: 504 
[458-600] vs. 479 [423-543], p=0.092; FCN-3: 9449 [5934-13070] vs. 8814 [5999-11006], 
p=0.837; MASP-2: 221 [129-369] vs. 208 [119-324], p=0.313). During this period, no 
significant change was observed between the different Child-Pugh stages either (p=1.000, using 
the Wilcoxon rank sum test). 
Lectin level measurements were performed in a different subgroup of 32 patients at the time of 
the AD episode. No significant difference was observed in the level of either molecule (FCN-2 
164 [107-284] vs. 178 [102-314], p=0.772; FCN-3: 6455 [3877-9204] vs. 5978 [3723-8751], 
p=0.400; MASP-2: 183 [106-329] vs. 167 [78-276], p=0.140). The median period between two 
samples was 555 days [133–955]. 
Significance of serum levels of lectin pathway molecules in the risk of clinically 
significant bacterial infections  
Ninety-five (35.7%) of involved patients encountered at least one episode of CSI during the 
follow-up period. The median time to the development of first infection was 626 [169-799] 
days.  Urinary tract infection was the most commonly diagnosed CSI and accounted for 33.7% 
of events, followed by spontaneous bacterial peritonitis (24.2%) and pneumonia (12.6%). 5.3% 
of the cases were multifocal. Other detected bacterial infections included erysipelas (4.2%), 
cholangitis (2.1%), bacteriaemia (2.1%) and acute bronchitis (3.2%), while the infection could 
not be located in 12 cases (12.6%). As regards the serum level of the lectin pathway molecules, 
it can be stated that FCN-2 and FCN-3 levels were lower than normal molecular levels and they 
correlated with the increasing cumulative incidence of clinically significant bacterial infections 
(FCN-2: 62.6% vs. 46.7% HR: 1.55, 95%CI: 1.00-2.39, p=0.047 and FCN-3: 59.3% vs. 48.2% 
HR: 1.61, 95%CI: 1.05-2.47, p=0.029)  
The serum ficolin profile, in the case of which both ficolins’ molecular levels were taken into 
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consideration simultaneously, showed a gradually increasing cumulative incidence in relation 
to the development of clinically significant bacterial infection, with the increase of the number 
of low ficolin levels: 45.7% (both ficolins at normal level), 57.2% (if one of the two ficolins 
was at a low level) and 63.8% (both ficolins at low level) (HR: 2.00, 95%CI: 1.15-3.47, 
p=0.016). No similar correlation was found either in the case of individual MASP-2 deficiency 
or MASP-2 deficiency combined with ficolins. 
The univariate Cox regression analysis of clinical factors related to the development of 
clinically significant bacterial infections revealed that alcoholic disease etiology (HR: 1.68, 
95%CI: 1.07-2.66, p=0.024), advanced disease stage (Child-Pugh stage B/C [HR: 2.42, 95%CI: 
1.61-3.64, p<0.001] or presence of ascites [HR: 2.31, 95%CI: 1.54-3.46, p<0.001]) and prior 
CSI episode (HR: 2.64, 95%CI: 1.76-3.96, p<0.001) were significantly associated with the 
increased risk for the development of CSI. However, the multivariate Cox regression analysis, 
which involved both the serum levels of lectin pathway molecules and the respective clinical 
variables, showed that only the clinical factors such as advanced disease stage and prior CSI 
episodes were proved to be independent risk factors in terms of the development of clinically 
significant bacterial infections, but this was not the case either in relation to each ficolin or the 
ficolin profile. 
We observed the potential effect of serum ficolin profile and MASP-2 deficiency on infection-
related mortality (n=95). 19 patients (20%) died during the first bacterial infection. According 
to the Kaplan-Meier survival test, neither the ficolin serum detected at the time of recruitment, 
nor the MASP-2 deficiency was in correlation with the risk of mortality. There were 85 cases 
of death related to liver diseases in the whole cirrhosis patient group (32. %). The Kaplan-Meier 
survival test showed that the chance of survival is significantly lower in the case of patients 
suffering from a more advanced stage of disease based on the Child-Pugh score (p<0.001), 
those who had already suffered from ascites (p<0.001) or prior CSI episodes (p=0.035). The 
MASP-2 deficiency (p =0.387) or the serum ficolin profile (p =0.093) was not in correlation 
with survival altogether. 
DISCUSSION 
Evaluation of antimicrobial antibodies in coeliac disease 
This is the first report to investigate the complex associations between a panel of new serological 
markers, clinical presentation of the disease, and NOD2/CARD15 status in a relatively large 
cohort of CD patients. The examination of antimicrobial antibody generation in coeliac patients 
can potentially be a new element of observing antibody generation.  
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In this study, we demonstrated that the presence of anti-glycan antibodies (gASCA, ACCA, and 
AMCA) are associated with CD at the time of diagnosis. However, the prevalence of ALCA 
and anti-OMP did not differ from the results in the control group. The rate of gASCA positivity 
(39%) at the time of diagnosis of CD was comparable to the results in CD patients in previous 
studies. 
Current data advocate that in both CD and Crohn’s disease patients have a primary defect in 
intestinal permeability that is also shared by a subgroup of relatives. In CD, it is also apparent 
that the exposure to gluten results in mucosal inflammation and the consequent tissue damage 
further abrogating the primary gut barrier defect, while gluten removal resolves the enhanced 
intestinal permeability. 
Comparing the data of coeliac patients with our own IBD patient population, no significant 
difference was noted between the two groups in terms of the prevalence of ASCA IgG (39% 
vs 50.5%, P = 0.091). In the present study, except ALCA, the occurrence of other anti-glycan 
antibodies and their median titers in CD at diagnosis was also similar to those observed in 
Crohn’s disease (celiac disease gASCA: 33.1 U/mL, AMCA 79.3 U/mL, ALCA 21.5 U/mL, 
ACCA 68.4 U/mL vs Crohn’s disease gASCA: 48.3 U/mL, AMCA 55.5 U/mL, ALCA 25.4 
U/mL, ACCA 46.2 U/mL). In addition, the positivity rate for any anti-glycan antibody was 
also comparable in these patient groups (CD vs Crohn’s disease: 65.9% vs 59.4%, P = NS). In 
addition, sensitivity, speci ficity, positive and negative likelihood ratios in celiac disease are 
comparable to that observed in Crohn’s disease. Consequently, in patients with gastrointestinal 
symptoms, the presence of gASCA, AMCA, or ACCA may not only suggest underlying 
Crohn’s disease but may also be associated with untreated CD. At the same time, and based on 
our results, ALCA and anti-OMP proved to be specific but relatively non-sensitive markers for 
Crohn’s disease.  
 
Current data advocate that in both CD and Crohn’s disease patients have a primary defect in 
intestinal permeability that is also shared by a subgroup of relatives. In CD, it is also apparent 
that the exposure to gluten results in mucosal inflammation and the consequent tissue damage 
further abrogating the primary gut barrier defect, while gluten removal significantly reduces 
or resolves the enhanced intestinal permeability. It is assumed that these gliadin-induced 
processes (intestinal barrier impairment) are the reasons for antibody generation in this disease. 
This assumption is further confirmed by the fact that a correlation was found between anti-
glycan markers and TGA or EMA in this study and also that the antibody status fundamentally 
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changed following the introduction of GFD. gASCA and other anti-glycan antibodies totally 
disappeared from the examined coeliac patients following the strict and long-term gluten-free 
diet. 
In the present study, we also established that the kinetics of antibody disappearance is variably 
sensitive to the length of GFD. Of the anti-glycan antibodies, AMCA and ACCA declined most 
rapidly, right after the TGA titer started to diminish. 
We evaluated the possible relationship between serological response and the clinical 
presentation of the disease. Patients with multiple seroreactivity to glycans, more commonly 
presented with severe malabsorption as compared to those without any reactivity against any 
glycan at all (63% vs 22%, P = 0.019), and accounted for 53% of all malabsorption cases. Among 
the patient groups, the TGA titer reached the highest value (115.9 U/mL vs others: 60.9 U/mL, 
P = 0.016) in those presenting with malabsorption, further supporting enhanced intestinal 
permeability as a likely component involved in antibody formation. It is well known that the 
intestinal damage is most pronounced in the malabsorption cases and TGA is a good marker for 
tissue injury. We must note however, that the number of subjects in different clinical 
presentation groups were limited, thus further studies with a larger cohort of CD patients are 
needed to confirm these findings.  
The latest data raise the possibility that the presence of antimicrobial antibodies may be at least 
partially related to genetic susceptibility. In coeliac patients, we did not observe any correlation 
with the presence of anti-glycan antibodies and the NOD2/CARD15 variant. An inheritable 
trait of anti-microbial antibody formation is unlikely in CD, since we did not find a higher 
prevalence of ASCA (9.1% vs 14%) and anti-OMP (12.1% vs 20%) as compared to the controls 
in the 66 unaffected, first-degree relatives (siblings) of this cohort.  
The presence of the serological response is assumed to be a reaction due to the permanent presence 
of the elements of intestinal microflora which resulted from increased bacterial translocation. The 
significance of the enhanced bacterial translocation out of the small bowel in the anti-microbial 
antibody formation is further supported by the fact that the presence of the serological response 
among patients with Crohn’s disease is mainly characteristic for those with complicated 
(stricturing or penetrating) small bowel involvement and is rarely observed in the isolated 
colonic disease or in patients with ulcerative colitis. At the same time, the recovered gut barrier 
function protects against the invasion of microbes or their components leading to the cessation 
of anti-microbial antibody formation. In CD, this process may be justified by the observation 
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that the serological response is a temporary phenomenon. Antibodies disappear completely as a 
result of the lack of gliadin exposition and the subsequent healing of the intestinal mucosa.  
Our data also call for additional basic research to explore the exact mechanism of immune 
responses to commensal enteric bacteria as well as the possible clinical significance of the 
bacterial translocation in the pathogenesis or the complications of these diseases as it is well 
established in other clinical conditions such as liver cirrhosis, acute pancreatitis or sepsis. 
 
Cirrhosis patients 
To our knowledge, this is, to date the largest study to investigate the complex association 
between serum levels of the lectin pathway molecules and the disease etiology along with 
severity in a large cohort of patients with cirrhosis. Of the lectin pathway of the complement 
system molecules, two sPRM (FCN-2 and FCN-3) and one effector molecule were evaluated 
(MASP-2).  
The serum level of lectin pathway shows high variability between individuals even in healthy 
subjects. In this study, the median MASP-2 level (102) and MASP-2 deficiency were identical 
to the previously disclosed values, while FCN-2 and FCN-3 levels were lower. This difference 
is supposedly due to the diversity of materials and methods used for this research. As for 
MASP-2, we used a commercially available assay widely used in complement/lectin studies. 
However, we used in-house double antibody sandwich ELISA to measure FCN-2 and FCN-3 
levels. 
In the large group of stable cirrhosis outpatients (n=266), we found that the serum levels of all 
three molecules were significantly lower than the healthy control group. 
Further explanations are needed to understand why the serum levels of cirrhosis patients 
decrease. According to one possible explanation, the synthetic capacity of hepatocytes is 
impaired in cirrhosis and the circulation is assumed to be blocked in the given organ, which 
results in reduced generation of molecules or their translocation into the peripheral blood. This 
assumption is confirmed by our result that the FCN-2, FCN-3 and MASP-2 levels gradually 
decrease in accordance with disease severity. There was a significant correlation between the 
laboratory characteristics of synthetic liver functions (serum albumin level and INR) and the 
various lectin levels which showed gradual decrease in accordance with disease severity. 
In this study, the observed lectin levels were permanently stable intraindividually and remained 
unchanged even in the early phase of acute decompensation (AD), which makes it possible to 
use them as serological biomarkers also in the long run. 
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Furthermore, we performed a follow-up study with the aim to examine whether the low level 
of ficolins or MASP-2 deficiency can be regarded as risk factors in cirrhosis patients from the 
aspect of the development of clinically significant infections. 
The FCN-2 and MASP2 gene promoters and their encoding regions involve numerous SNPs, 
which has an impact on protein concentration, but relatively few SNPs were identified on the 
FCN-3 gene. 
It is clearly shown that genotype has a very little influence on average protein concentration. 
Apart from gene polymorphisms, the up/downregulation of these genes and the 
decrease/increase of serum proteins seem to be in correlation with various inflammatory and 
infectious diseases. Furthermore, it remains to be determined whether the non-genetic 
influence is as strong as genotype or even stronger. Due to these limiting factors, we analysed 
the serum levels of lectin pathway molecules instead of genotyping. If serological markers are 
used for long-term forecasting, it is important that the serum levels of this molecule are stable 
at least for a certain period of time and under certain circumstances. Accordingly, we 
determined the stability of FCN-2, FCN-3 and MASP-2 serum levels in a subgroup of patients. 
The median period between samplings could be compared to the period of time until the 
appearance of the first clinically significant bacterial infection. Neither of the serum levels of 
these molecules showed any significant change after this period has passed. There were no 
significant change either in the severity of disease during this observable period. 
The low level of pattern recognition molecules leads to the insufficient recognition of microbes 
and reduced complement activation, opsonisation and inflammatory cytokine secretion, which 
results in increased susceptibility to infections. For this reason, it is rational to assume that the 
serum levels of lectin pathway molecules may correlate with the bacterial infection episodes 
of cirrhosis patients, but this aspect has not been studied yet. In the patient group examined by 
us, the cumulative probability of clinically significant bacterial infections was significantly 
higher in the case of subjects with reduced FCN-2 or FCN-3 level and it further intensified if 
the levels of both lectins were low. This correlation was not independent of disease severity. 
These results suggest that reduced ficolin levels are the consequence of the impairment of the 
liver cells’ synthetic capacity in advanced cirrhosis and there is no substitute which could make 
up for their function. For this reason, lectin deficiencies can be considered important adaptive 
components of cirrhosis-related immune deficiency. However, it cannot be excluded that other 
soluble pattern recognition molecules which similarly activate the alternative pathway, but 
recognise other epitopes (MBL, M-ficolin, collectin 10 and 11) are able to ease the 
immunological impact of FCN deficiency to some degree. 
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From the prognostic point of view, our results did not convey any new information, but these 
new findings are significant from the pathological aspect. Soluble pattern recognition molecules 
(sPRMs) may be the targets of non-antibiotics-based infection prophylaxis. In advanced 
cirrhosis, when liver functions cannot be improved without liver transplantation, the correction 
of cirrhosis-associated immune dysfunction syndrome components can potentially decrease the 
frequency of developing infections which generally lead to death. In the case of MBL 
deficiency, the restoration of the MBL level improved survival and it was proved to be safe and 
efficient both in preclinical and early phase II studies. Performing similar studies could be of 
significant value in the case of ficolin deficiency. 
In this study, the MASP-2 levels did not correlate with the frequency of clinically significant 
infections. It is undoubtedly the limiting factor of our study that no functional analysis was 
performed. For this reason, the possibility of correlation between MASP-2 activity and the 
examined clinical parameters cannot be excluded.  
The serum level of lectin pathway molecules at the time of including patients did not show any 
correlation with infection-related mortality. Since complement system presents a dual role in 
disease susceptibility, one can expect that during on-going inflammatory process rather its 
excessive activation with subsequent tissue damage than its lack of activity might be harmful. 







MAIN NEW SCIENTIFIC FINDINGS 
Coeliac disease 
 1. In coeliac disease, the appearance of anti-glycan antibodies is frequent at the time of 
setting up the diagnosis before starting the treatment.  
 2. The prevalence of antibodies and their titer values are very similar to those observed 
in Crohn’s disease and correlate with the clinical appearance of the disease, but not with the 
presence of the NOD2/CARD15 mutation.  
 3. The highest anti-glycan antibody prevalence and titer values can be be observed in 
the case of malabsorption, a disease which has the most severe clinical form.  
 4. As a result of a sufficiently long and proper gluten-free diet, antibodies totally 
disappear from the serum.  
 5. The appearance of anti-glycan antibodies is not more frequent in the healthy first 
degree relatives of coeliac patients. 
 6. Based on our findings, ASCA and other anti-glycan antibodies can be regarded as the 
supplementary markers of coeliac disease and gluten-free diet compliance. 
 
Cirrhosis 
1. We were the first to report on the lectin complement pathway molecules in a large 
cirrhosis patient group in a complex way. Serum lectin levels correlate with the severity of liver 
disease and the prevalence of portal hypertension. Lectin levels did not correlate with the 
etiology of cirrhosis. 
2. In this study, the observed lectin levels were permanently stable intraindividually and 
remained unchanged even in the early phase of acute decompensation, which makes it possible 
to use them as serological biomarkers also in the long run. 
3. These results suggest that reduced ficolin levels are the consequence of the 
impairment of liver cells’ synthetic capacity in advanced cirrhosis and there is no substitute 
which could make up for their function. For this reason, lectin deficiencies can be considered 
new adaptive components of cirrhosis-related immune deficiency. 
4. From the prognostic point of view, our results did not convey any new information 
compared to the currently available clinical prognostic factors and they are not suitable for 
inclusion into the matrix model of risk assessment, because they cannot be used as independent 
risk factors in infection prognosis. 
5. Lectins may be the targets of non-antibiotics-based infection prophylaxis in 
cirrhosis patients. 
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